A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798.
Phase of Trial: Phase II
Latest Information Update: 02 May 2016
At a glance
- Drugs PF 232798 (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 03 Nov 2008 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
- 17 Oct 2007 Status change frim recruting to completed.